CORPORATE

Fondazione Toscana Life Sciences, a non-profit organisation specialising in the establishment of new pharmaceutical/biotechnological ventures, and Kedrion, a biopharmaceutical company specialising in the development and manufacture of plasma-derived products, announced they have entered into an agreement under which Kedrion will be granted a biopharmaceutical production laboratory in accordance with the GMPs – Good Manufacturing Practices,

The Biological Safety Centre – BioSC, specialized in viral validation studies, more specifically “studies for inactivation/removal of viral and non-viral pathogens (prions) for biological and biotechnological productions” for in-house and outsourced services, has been opened. BioSC’s mission is to respond with full capabilities to the current and future requirements in terms of safety from biological

The Board of Directors of Kedrion SpA – specialising in the development, manufacture and distribution of plasma derived medicinal products, led by Paolo Marcucci, President and CEO – met today to approve the 2009 Financial Statements. In the financial year 2009, Kedrion Group achieved some major results, despite the challenging scenario, retaining its leading position

Kedrion Group’s growth strategy is progressing in two directions: one is the vertical integration of its operations, the other is the expansion of its production capacity aimed at consolidating its international market share, especially in Europe. The start of the upgrading and expansion of the Gödöllo plant, commissioned to the Engineering Company Foster Wheeler Italiana

AIFA, the Italian Medicine Agency, will give the incentives planned under the 2008 framework agreements to seven investment plans submitted by Kedrion, a biopharmaceutical company which is the national leader in the development, manufacture and distribution of plasma derivative medicines. This accolade by AIFA – which has allocated 3,184,025 euros’ worth of resources to investments

The investments for the continuous improvement of the manufacturing processes and plants of Kedrion are going on at a fast pace. After passing the AIFA inspection (AIFA is the Italian Drugs Agency) and proving to comply with international Good Manufacturing Practices (GMP), the process for the authorisation to operate with four new departments in the

 Paolo Marcucci, President and CEO of Kedrion, has joined the Global Board of Directors of the Plasma Protein Therapeutics Association (PPTA). “We are excited that Mr. Marcucci is joining the Global Board of Directors” said Jan M. Bult, PPTA’s President. “Paolo Marcucci understands the many challenges confronting our industry and the patients we serve. He

Kedrion embarks on its second technology transfer to Russia following the one in Kirov, by signing an agreement in Moscow for the development of a plasma-derivatives production plant to the highest international quality, safety and efficiency standards. The agreement signed between Kedrion, the Dutch company BTI and the Moscow Government covers both the engineering operations

Kedrion SpA has bought yesterday from Teva Pharmaceutical Industries Ltd (a leading global pharmaceutical company) 100% of the shares in Human Bioplazma Manufacturing and Trading Ltd, a company established under the Hungarian law and based in Gödöllo (Budapest). Kedrion thus acquires a manpower of 127 employees, a fractionation and production plant with a productive capacity

Kedrion has recently finalised two important agreements for the purchase of four plasma collection centres, two in the United States (Florida and Alabama) and two in Germany (Bavaria). The agreement to buy the two US centres, Pensacola (Florida) and Mobile (Alabama), has been signed with Life Therapeutics, a leader in plasma collection for therapeutic and